FDA Rejects Outlook Therapeutics’ Proposed Treatment for Wet AMD
Outlook Therapeutics faced a major setback on Wednesday as the U.S. Food and Drug Administration (FDA) rejected its proposed treatment for wet age-related macular degeneration (AMD). The biopharmaceutical company's shares…